| Autor: |
Jones, David, Boudes, Pol F, Swain, Mark G, Bowlus, Christopher L, Galambos, Michael R, Bacon, Bruce R, Doerffel, Yvonne, Gitlin, Norman, Gordon, Stuart C, Odin, Joseph A, Sheridan, David, Wörns, Markus-Alexander, Clark, Virginia, Corless, Linsey, Hartmann, Heinz, Jonas, Mark E, Kremer, Andreas E, Mells, George F, Buggisch, Peter, Freilich, Bradley L, Levy, Cynthia, Vierling, John M, Bernstein, David E, Hartleb, Marek, Janczewska, Ewa, Rochling, Fedja, Shah, Hemant, Shiffman, Mitchell L, Smith, John H, Choi, Yun-Jung, Steinberg, Alexandra, Varga, Monika, Chera, Harinder, Martin, Robert, McWherter, Charles A, Hirschfield, Gideon M |
| Zdroj: |
The Lancet Gastroenterology & Hepatology; 20240101, Issue: Preprints |
| Abstrakt: |
Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid. Seladelpar is a potent, selective agonist for the peroxisome proliferator-activated receptor-delta (PPAR-δ), which is implicated in bile acid homoeostasis. This first-in-class study evaluated the anti-cholestatic effects and safety of seladelpar in patients with an inadequate response to ursodeoxycholic acid. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
